Nature Communications (Apr 2018)

HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis

  • Margaux Sevin,
  • Lucia Kubovcakova,
  • Nicolas Pernet,
  • Sébastien Causse,
  • Franck Vitte,
  • Jean Luc Villeval,
  • Catherine Lacout,
  • Marine Cordonnier,
  • Fernando Rodrigues-Lima,
  • Gaétan Chanteloup,
  • Matthieu Mosca,
  • Marie-Lorraine Chrétien,
  • Jean Noël Bastie,
  • Sylvain Audia,
  • Paul Sagot,
  • Selim Ramla,
  • Laurent Martin,
  • Martin Gleave,
  • Valérie Mezger,
  • Radek Skoda,
  • Isabelle Plo,
  • Carmen Garrido,
  • François Girodon,
  • Aurélie de Thonel

DOI
https://doi.org/10.1038/s41467-018-03627-9
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 13

Abstract

Read online

Myelofibrosis is a chronic degenerative disorder characterized by progressive bone marrow fibrosis. Here, the authors show that the chaperone HSP27 contributes to myelofibrosis via regulation of the JAK2/STAT5 pathway, and that antisense oligonucleotides targeting HSP27 are effective in two mouse models of the disease